Co-infections and pulmonary inflammation are potentially life-threatening consequences of COVID-19. We believe that for the management of co-infections, macrolide antibiotics are particularly useful. Although azithromycin is actively being pursued,1 we would also like to suggest josamycin as a worthwhile alternative. Both macrolides are indicated for the treatment of a variety of respiratory infections including pharyngolaryngitis, acute bronchitis, and pneumonia, and the minimum inhibitory concentration of these drugs for the treatment of these infections are rapidly reached in the lungs.
No takes yet. Share an insight, caveat, or question.
Sterenczak et al. (2020) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: